Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
Rhea-AI Summary
Foghorn Therapeutics (Nasdaq: FHTX) will present new preclinical data at the 2026 AACR Annual Meeting April 17–22, 2026 in San Diego. Data include a selective SMARCA2 inhibitor FHD-909 (combination potential with anti-PD-1 in SMARCA4-mutant lung cancer) and multiple degrader programs: CBP (FHT-171), EP300, and ARID1B.
Oral and poster sessions list presenters, session times, and poster numbers; materials will be accessible in the company’s Science section online.
Positive
- None.
Negative
- None.
News Market Reaction – FHTX
On the day this news was published, FHTX declined 2.04%, reflecting a moderate negative market reaction. Argus tracked a trough of -3.2% from its starting point during tracking. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $6M from the company's valuation, bringing the market cap to $274.72M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed moves: ALEC -6.2%, CAPR -3.86%, NGNE -1.55% down while OMER +1.59% and MNPR +4.3% are up. Only one peer (MREO +3.23%) appears in the momentum scanner, supporting a stock-specific read for FHTX.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 11 | Financial & outlook update | Positive | -12.9% | 2025 financial update and 2026 strategic outlook with extended runway. |
| Feb 24 | Investor conferences | Neutral | -1.4% | Participation in TD Cowen and Citizens life sciences investor conferences. |
| Feb 23 | CFO appointment | Positive | +0.3% | Appointment of experienced CFO Ryan Maynard with strong financing track record. |
| Feb 03 | Conference participation | Neutral | -2.7% | Announcement of presentation at Guggenheim Emerging Outlook: Biotech Summit. |
| Jan 13 | Registered direct financing | Negative | -5.5% | Closing of $50M equity and warrant financing at a 30% premium. |
Recent news often saw negative or muted price reactions, even to seemingly positive pipeline and financing updates.
Over the last few months, Foghorn reported multiple pipeline and corporate updates. A Jan 13, 2026 registered direct financing of $50M at a 30% premium saw the stock fall 5.54%. Subsequent conference participation headlines in February 2026 had modest negative moves. Appointment of a new CFO on Feb 23, 2026 with strong capital‑markets experience produced only a small 0.35% gain. A Mar 11, 2026 financial/strategic update, including extended cash runway, was followed by a 12.92% drop, suggesting a tendency toward weak reactions even on constructive news.
Market Pulse Summary
This announcement highlights Foghorn’s breadth of early‑stage oncology work, including FHD‑909 and selective CBP, EP300, and ARID1B degraders with multiple oral and poster slots at AACR 2026. In recent filings, the company underscored a Phase 1 trial for FHD‑909 and a portfolio still in precommercial stages, which carries typical biotechnology risks such as funding needs and clinical uncertainty. Investors may watch for subsequent clinical readouts, regulatory interactions, and future financing steps that follow these preclinical data presentations.
Key Terms
preclinical medical
smarca2 inhibitor medical
smarca4-mutant medical
anti-pd-1 antibody medical
hematologic malignancies medical
targeted protein degradation medical
epigenetic modulators medical
chromatin regulatory proteins medical
AI-generated analysis. Not financial advice.
New preclinical data for FHD-909 (LY4050784) reinforcing the potential for expansion opportunities in combination with an anti-PD-1 antibody in SMARCA4 (BRG1)-mutant lung cancer
Preclinical characterization of FHT-171, a selective CBP degrader with promise in ER+ breast cancer
Progress across Selective EP300 degrader in hematological malignancies and
Selective ARID1B degrader in ARID1A-mutant tumors
WATERTOWN, Mass., April 09, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that it will have multiple oral and poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting being held April 17-22, 2026, in San Diego, California. New preclinical data for Selective SMARCA2 inhibitor FHD-909 will be featured as part of an oral presentation and preclinical data for Selective CBP, Selective EP300, and Selective ARID1B degrader programs will be featured as poster presentations.
“FHD-909 is advancing in the clinic in collaboration with Lilly as the first potential selective SMARCA2 inhibitor for the treatment of SMARCA4-mutant cancers. We are excited to present new, compelling preclinical data further supporting potential expansion opportunities in combination with an anti-PD-1 antibody, as part of Dr. Bellon’s oral presentation at this year’s AACR,” said Adrian Gottschalk, President, and Chief Executive Officer of Foghorn. “Poster presentations will also highlight additional preclinical data characterizing our wholly owned Selective CBP, Selective EP300, and Selective ARID1B degrader programs. Collectively, these data underscore the differentiated profiles of our pipeline programs which may translate to improved therapeutic outcomes for difficult to treat cancers with significant unmet need.”
Oral Presentation Details
Title: Targeting chromatin regulatory proteins in hematologic malignancies
Town Meeting: Chemistry, Hematologic Malignancies – From Molecules to Medicine – Driving Breakthroughs in Blood Cancer Treatment: A CICR-HMWG Town Hall
Session Date/Time: Monday, April 20, 6:30 p.m. – 8:30 p.m. PDT
Presenter: Gromek Smolen, VP, Biology, Foghorn Therapeutics
Title: Leveraging paralog relationships for targeting chromatin modulators in cancer: ARID1B and SMARCA2 (FHD-909)
Session: Molecular/Cellular Biology and Genetics, Chemistry, Drug Development – Synthetic Lethality in Oncology: Progress Made, Pitfalls Encountered, and the Path Forward
Session Date/Time: Tuesday, April 21, 10:15 a.m. – 11:45 a.m. PDT
Presenter: Steven Bellon, Chief Scientific Officer, Foghorn Therapeutics
Title: Towards new cancer medicines with degraders of chromatin regulatory proteins
Session: Chemistry, Drug Development, Experimental and Molecular Therapeutics – Induced Proximity Pharmacology: Degraders and Beyond
Session Date/Time: Wednesday, April 22, 10:15 a.m. – 11:45 a.m. PDT
Presenter: Danette Daniels, VP, Degrader Platform, Foghorn Therapeutics
Poster Presentation Details
Title: Preclinical evaluation of selective and potent EP300 degraders demonstrates robust antitumor activity and favorable tolerability in hematologic malignancies
Session: Experimental and Molecular Therapeutics – Quantitative Pharmacology and Translational Modeling
Poster Number: 1828 / 16
Session Date/Time: Monday, April 20, 9:00 a.m. – 12:00 p.m. PDT
Presenter: Meiyun Lin, Senior Scientist, Pharmacology, Foghorn Therapeutics
Abstract: Click here
Title: Leveraging selective degradation of CBP and EP300 for potent anti-cancer activity
Session: Chemistry – Targeted Protein Degradation and Induced Proximity
Poster Number: 5163 / 13
Session Date/Time: Tuesday, April 21, 9:00 a.m. – 12:00 p.m. PDT
Presenter: Karolina Mizeracka, Principal Scientist, Cell Biology, Foghorn Therapeutics
Abstract: Click here
Title: Identification of first-in-class selective ARID1B degraders
Session: Experimental and Molecular Therapeutics – Proximity-Induced Drug Discovery 2
Poster Number: 5792 / 19
Session Date/Time: Tuesday, April 21, 2:00 p.m. – 5:00 p.m. PDT
Presenter: Madeleine Henley, Senior Scientist, Foghorn Therapeutics
Abstract: Click here
Title: Preclinical characterization of FHT-171, a first-in-class degrader targeting CREB-binding protein (CBP) in CBP-dependent solid tumors
Session: Experimental and Molecular Therapeutics – Epigenetic Modulators 2
Poster Number: 7075 / 22
Session Date/Time: Wednesday, April 22 9:00 a.m. – 12:00 p.m. PDT
Presenter: Darshan Sappal, Director, Biology, Foghorn Therapeutics
Abstract: Click here
Dr. Bellon’s presentation and the posters will be accessible under the Science section of the Company’s website.
About Foghorn Therapeutics
Foghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control® platform, Foghorn is systematically studying, identifying, and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website at www.foghorntx.com for more information on the Company, and follow us on X and LinkedIn.
Forward-Looking Statements
This press release contains “forward-looking statements.” Forward-looking statements include statements regarding the Company’s ongoing Phase 1 trial of FHD-909 in SMARCA4-mutated cancers, pre-clinical product candidates, expected timing of clinical data, expected cash runway, expected timing of regulatory filings, and research efforts and other statements identified by words such as “could,” “may,” “might,” “will,” “likely,” “anticipates,” “intends,” “plans,” “seeks,” “believes,” “estimates,” “expects,” “continues,” “projects” and similar references to future periods. Forward-looking statements are based on our current expectations and assumptions regarding capital market conditions, our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, actual results may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global political, economic, business, competitive, market and regulatory conditions, including risks relating to our clinical trials and other factors set forth under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the Securities and Exchange Commission. Any forward-looking statement made in this press release speaks only as of the date on which it is made.
Contact:
Karin Hellsvik, Foghorn Therapeutics Inc.
